Stifel Financial Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call
Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market opens on Wednesday, January 29, 2025. The company will host a conference call ...
Stifel maintains Buy on Revolve stock with $41 target
Stifel analysts kept a Buy rating on Revolve Group (NYSE:RVLV) shares, maintaining a $41.00 price target. The firm is ...
Canada’s Eight Capital to Shut Down as Stifel Swoops In for Bankers
Canadian investment dealer Eight Capital Corp. is winding down and many of its top staff are headed to Stifel Financial Corp.
Fastenal price target lowered to $82 from $86 at Stifel
Stifel lowered the firm’s price target on Fastenal (FAST) to $82 from $86 and keeps a Hold rating on the shares. Despite the ...
Stifel maintains Parker-Hannifin stock Hold rating, $691 target
Stifel analysts maintained a Hold rating on Parker-Hannifin shares (NYSE:PH) with a steady price target of $691. The decision ...
Edgewise Therapeutics initiated with a Hold at Stifel
Stifel initiated coverage of Edgewise Therapeutics (EWTX) with a Hold rating and $30 price target The firm says that while Edgewise has “very ...
Rapid7, Tenable cut to Hold at Stifel on low priority of vulnerability management
Stifel downgrades cybersecurity stocks Rapid7 and Tenable to Hold, citing cautious stance on vulnerability management.
24/7 Wall St1d
2025 Bull Market: Here's How High These Wall Street Analysts Think the Market Could Go In 2025
Wall Street analysts are buzzing with optimism as we step into 2025.  There are plenty of reasons for a positive view to ...
Legal Sports Report5d
Stifel Initiates FanDuel Parent Flutter With Buy Rating
Stifel initiated coverage of FanDuel parent company Flutter Thursday with a $320 target price and a buy rating.
What Analysts Are Saying About Stifel Financial Stock
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.
Hosted on MSN2h
Deregulation will help growth and tap down inflation, Stifel CEO says
Stifel CEO Ron Kruszewski discusses deregulation, economic growth, his expectations for the Federal Reserve handling of rates ...